Morningstar - Hong Kong Exchanges Clearing Ltd. (00388) HKExs 2Q Results Boosted by Higher Turnover in Equity Market; Stock Remains Overvalued

Report

Morningstar

Michael Wu

EUR 101.80 For Business Accounts Only

HKEx's 2Q Results Boosted by Higher Turnover in Equity Market; Stock Remains Overvalued

A sustained improvement in investor sentiments, along with the symbolic inclusion of A-shares in the MSCI index, lifted equity turnover in the quarter, along with wide-moat Hong Kong Exchange and Clearing's second-quarter result. In line with our expectation at the first-quarter result that investment sentiments will be supportive for the remainder of the year, average daily turnover in the domestic market improved to HKD 79.5 billion, compared with HKD 73.7 billion in the first quarter and much...

09/08/2017 14 EN

Underlying

Hong Kong Exchanges & Clearing Ltd.

Hong Kong Exchanges and Clearing is an exchange controller under the Securities and Futures Ordinance. Co. operates recognised stock and futures markets in Hong Kong. Co. also operates Hong Kong Securities Clearing Company Limited (HKSCC), HKFE Clearing Corporation Limited (HKCC), The SEHK Options Clearing House Limited (SEOCH) and OTC Clearing Hong Kong Limited (OTC Clear). HKSCC, HKCC and SEOCH provide clearing and settlement services, while OTC Clear provides OTC interest rate derivatives and non-deliverable forwards clearing and settlement services. Co.'s operating segment include: cash, equity & financial derivatives, commodities, clearing, and platform & infrastructure.

See profile

HK0388045442 Hong Kong Stock Exchange Hong Kong

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Michael Wu

Other Reports on these Companies

UOB

Hong Kong Exchanges and Clearing (388 HK): 2Q25: Record-high bottom line; strong ADT momentum continues in 2H25.

HKEX’s 2Q25 results were a beat due to better NII on forex gains and prudent cost control. Core revenue came in strong as expected, thanks to high headline ADT in 2Q25. We are positive on the 2H25 ADT outlook, driven by favourable liquidity conditions amid the rate cut cycle, strong Southbound flow and pick-up in IPO pipeline. We expect potential upward revisions to consensus earnings estimates, alongside further valuation re-rating. Maintain BUY with a 10% higher target price of HK$518.00.

August 21, 2025 August 21, 2025 1 EN

UOB

Greater China Daily: Thursday, August 21, 2025

KEY HIGHLIGHTS Results Baidu Inc (9888 HK/HOLD/HK$87.25/Target: HK$88.00) Baidu’s 2Q25 earnings missed our expectations. Revenue dropped 4% yoy to Rmb32.7b, in line with consensus estimates. Gross margin dropped 8ppt yoy to 43.9%, below consensus expectations. Non-GAAP operating profit was Rmb4.4b, plunging 41% yoy, while non-GAAP operating profit margin came in at 14%. Non-GAAP net profit slumped 35% yoy to Rmb4.8b, beating consensus forecasts. Maintain HOLD with an unchanged target price of HK$88.00 (US$98.00). China Longyuan Power (916 HK/HOLD/HK$6.87/Target: HK$6.80) Longyuan reported 1...

August 21, 2025 August 21, 2025 1 EN

UOB

Regional Morning Meeting Notes: Thursday, August 21, 2025

GREATER CHINA Results Baidu Inc (9888 HK/HOLD/HK$87.25/Target: HK$88.00): 2Q25: Earnings missed expectations; release of next-gen Ernie bot in 2H25. Crystal International (2232 HK/BUY/HK$6.08/Target: HK$7.07): 1H25: Continuous margin expansion; strong order visibility into 3Q26. Fuyao Glass Industry Group (3606 HK/BUY/HK$67.50/Target: HK$85.00): 2Q25: Core earnings beat estimates by 8%. Maintain BUY. Raise target price from HK$68.00 to HK$85.00. Hong Kong Exchanges and Clearing (388 HK/BUY/HK$441.20/Target: HK$518.00): 2Q25: Record-high bottom line; strong ADT momentum continues in 2H25. Kings...

August 21, 2025 August 21, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

HKEx's 2Q Results Boosted by Higher Turnover in Equity Market; Stock Remains Overvalued

Hong Kong Exchanges and Clearing (388 HK): 2Q25: Record-high bottom line; strong ADT momentum continues in 2H25.

Greater China Daily: Thursday, August 21, 2025

Regional Morning Meeting Notes: Thursday, August 21, 2025

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe